– USA, MD – REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel Tassé to its board of directors, effective August 15, 2016.
“On behalf of the board of directors, I am pleased to welcome Daniel to REGENXBIO. Daniel’s extensive global executive experience and knowledge of the biopharmaceutical industry will be of great value as REGENXBIO advances its gene therapy treatments into the clinic,” said Don Hayden, Chairman of REGENXBIO’s board of directors.
Mr. Tassé has more than 20 years of biopharmaceutical leadership experience, including his current role as Chairman and Chief Executive Officer of Alcresta Therapeutics, Inc. Previously, Mr. Tassé was Chairman and Chief Executive Officer of Ikaria, Inc., prior to its acquisition by Mallinckrodt Pharmaceuticals. He has also held leadership roles at Baxter International Inc. and GlaxoSmithKline plc.
“I am pleased to be joining REGENXBIO’s board at this exciting time for both the company and the gene therapy field,” said Mr. Tassé. “I look forward to contributing to REGENXBIO’s continued success as the company advances its innovative gene therapies in areas of significant unmet need.”
Mr. Tassé earned a B.S. in biochemistry from the University of Montreal. He currently serves as a member of the boards of directors at Bellerophon Therapeutics, Inc., and Indivior PLC. Mr. Tassé has previously been a member of the Healthcare Leadership Council, the Health Section Governing Board of the Biotechnology Innovation Organization and the board of directors of the Pharmaceutical Research and Manufacturers of America.
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of June 30, 2016, REGENXBIO’s NAV Technology Platform was being applied in the development of 29 product candidates for a variety of diseases, including five internally developed candidates and 24 partnered candidates developed by REGENXBIO’s licensees.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.